Analysts Set Alamar Biosciences, Inc. (NASDAQ:ALMR) PT at $30.00

Shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) have received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $30.00.

A number of research analysts have commented on ALMR shares. Leerink Partners assumed coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set an “outperform” rating and a $35.00 target price on the stock. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. Bank of America assumed coverage on shares of Alamar Biosciences in a research note on Tuesday, May 12th. They set a “neutral” rating and a $27.00 price objective on the stock. TD Cowen began coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Zacks Research raised shares of Alamar Biosciences to a “hold” rating in a research note on Wednesday, May 13th.

Alamar Biosciences Trading Down 1.7%

Shares of NASDAQ ALMR opened at $25.23 on Wednesday. Alamar Biosciences has a twelve month low of $18.84 and a twelve month high of $28.68. The company has a market cap of $1.75 billion and a price-to-earnings ratio of -14.50. The firm’s fifty day moving average price is $22.69.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings results on Friday, May 8th. The company reported ($1.74) EPS for the quarter. The firm had revenue of $26.04 million during the quarter.

Insider Buying and Selling at Alamar Biosciences

In related news, Director Nicholas Naclerio acquired 235,294 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $3,999,998.00. Following the purchase, the director directly owned 507,076 shares of the company’s stock, valued at $8,620,292. This trade represents a 86.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the business’s stock in a transaction on Monday, April 20th. The stock was bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the purchase, the insider directly owned 507,076 shares of the company’s stock, valued at $8,620,292. The trade was a 86.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.